
The drugmaker reported higher third-quarter revenue and profit, and plans annual savings of $1.5 billion for reinvestment in its business.
AstraZeneca’s profit after tax rose 23% to $3.12 billion in the third quarter, as sales of cancer medicines helped drive revenue up 7% to $16.2 billion. The company also announced a plan to deliver $1.5 billion in annual savings.
Oncology sales increased 17% to $7.8 billion, accounting for 48% of revenue. AstraZeneca said Tagrisso and Imfinzi led growth in the division. Core earnings per share rose 17% to $2.79.
The savings plan will incur up to $2 billion in one-off restructuring charges and is due to be largely complete by the end of 2029. AstraZeneca said it intends to reinvest the savings, mainly in its drug development pipeline. It has not announced job cuts.
Sales of Farxiga fell 25% to $1.6 billion after cheaper generic versions entered the US market. The company also cited pressure from China’s bulk-buying scheme. AstraZeneca confirmed its 2026 outlook, forecasting mid-to-high single-digit revenue growth and low double-digit growth in core earnings per share, excluding currency movements.
As of 14:49 UTC on Friday, AstraZeneca shares traded at 13,824 pence, up 5.91% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.